Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 1998

View Archived Issues

PAF antagonists in the treatment of asthma: promise or hype?

Onconase and proteasome inhibitors have synergistic antitumor activity, even in resistant tumors

Ligand files new drug submission for Panretin Gel in Canada

Coulter initiates expanded access program for Bexxar

HER2 diagnostic test approved in U.S.; will help identify candidates for Herceptin therapy

Targeted Genetics initiates phase II trials for proprietary gene therapy compound

Orphan Medical's Busulfex Injection granted priority review

Yoshitomi: Annual Report 1998

New orally active antitumor platinum complexes synthesized at SS Pharm.

Gruenenthal develops new opioid analgesics

Akzo describes selective 5-HT2C agonists for depression and other CNS disorders

Dual TxA2 antagonists and NO donors and their use disclosed by ADIR

New series of beta-agonists in early development at Yamanouchi

Use of rPAF-AH in necrotizing colitis, ARDS and acute pancreatitis

Elan completes acquisition of NanoSystems

ThromboSol effectively preserves platelet function and cell recovery in in vivo study

Radiolabeled peptide from Diatide effectively pinpoints site of infection

Long-term ETA receptor blockade shows detrimental effects on LV remodeling

Genotyping accurately predicts response to treatment with 5-LO inhibitor

ZK-137316: chronic, low-dose regimen prevents pregnancy in monkeys with little cycle disruption

Anti-IgE antibody in the treatment of asthma: an interesting theory is validated

Lilly to pursue new indication for Zyprexa despite FDA nonapprovable letter

Novel antiepileptic agent developed by SK enters clinical trials

Actonel now available for treatment of Paget's disease

Pivotal trial of exisulind for prostate cancer recurrence fully enrolled

InKine colonic purgative proceeds to phase III trials

Cytogen anticipates selection of new marketing partner for Quadramet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...